***Background.*** In 2014, an outbreak of enterovirus D68 (EV-D68) caused severe respiratory illness in the United States. To date most of the data have been derived from small case series that included previously healthy children or those with asthma. The burden of EV-D68 in children with other chronic complex medical conditions (CCMC) is not well characterized.

***Methods.*** From May 2014 to November 2014 nasopharyngeal (NP) samples from pediatric patients that detected rhinovirus/enterovirus (RV/EV) by the FilmArray Respiratory Panel (BioFire Diagnostics) were tested for EV-D68 by real time PCR. Demographic, clinical, and outcome data were reviewed.

***Results.*** 431 NP samples detected RV/EV in hospitalized children with acute respiratory infections. EV-D68 was detected in 177 (41%) patients (median age 4.7 years; 58% males) including: (1) 65 (37%) with CCMC \[genetic syndromes (20, 31%), congenital heart disease (16, 25%), prematurity (15, 23%), immunocompromised (8, 12%), neurologic disorders (6, 9%)\]; (2) 72 (41%) with asthma; and (3) 40 (23%) previously healthy. EV-D68 semiquantitative viral loads (ct) were similar between groups (table). Co-pathogens were detected in 3 of 177 (1.7%) patients (influenza A, coronavirus and parainfluenza). Asthmatic children, but not those with CCMC or previously healthy were more likely to require PICU admission (p \< .001), non-invasive ventilation (p = .01), and supplemental O~2~ (p = .006). Duration of hospitalization was similar between healthy and asthmatic children but longer in CCMC children (p \< .0001). No cases of acute flaccid myelitis were identified.

                                    Healthy n = 40     Asthma n = 72      CCMC n = 65        *P* value
  --------------------------------- ------------------ ------------------ ------------------ -----------
  Age (y)                           4.3 (1.3-7.05)     5.6 (3.2-8.5)      4.7 (1.4-7.8)      .057
  PICU, n (%)                       21 (52.5)          62 (86.1)          42 (64.6)          .0004
  LOS (d)                           2.2 (1.8-2.9)      2.9 (1.9-4.2)      3.7 (2.4-7.5)      \<.0001
  Supplemental O~2~, n (%)          18 (45)            54 (75)            40 (61.5)          .006
  Non-invasive ventilation, n (%)   7 (17.5)           33 (45.8)          26 (40.0)          .010
  EV-D68 Ct values                  24.9 (20.9-28.5)   26.9 (23.4-29.8)   24.8 (20.7-30.1)   .131

Continuous variables are displayed as median IQR.

***Conclusion.*** To our knowledge, this is the largest reported case series of children with EV-D68. The majority of infected children had asthma or CCMC. The clinical course of EV-D68 infection was not more severe in CCMC children, including immunucompromised patients. However, EV-D68 patients with asthma required more aggressive management, suggesting that asthma is a significant risk factor for severe EV-D68 disease.
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